Evaluation of the efficacy as well as prognosis of targeted therapy for advanced non-small cell lung cancer patients with different expression of miR-183 family in body fluids

Aim To explore the relationship between the expression of miR-183 family in body fluids and the treatment effect and prognosis of advanced non-small cell lung cancer (NSCLC) patients received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Methods One hundred and fifty advanced NSCLC patients were selected as the study subjects, all of whom received EGFR-TKI osimertinib. The efficacy of all NSCLC patients was evaluated after 2 courses of treatment, and the patients were allocated into effective group ( n = 40) and ineffective group ( n = 110). Real-time fluorescence quantitative PCR detected the relative expression of serum miR-183 in both groups. The EGFR-TKI efficacy of NSCLC patients with different clinical characteristics along with the survival rate of patients with different serum miR-183 relative expression levels before treatment was compared. Multivariate Cox regression model was implemented to analyze the factors affecting survival of NSCLC patients after EGFR-TKI treatment. Results After treatment, serum miR-183 expression in effective group was declined relative to before treatment and ineffective group, and serum miR-183 expression in ineffective group was elevated compared to before treatment (all P < 0.05). The EGFR-TKI efficacy of NSCLC patients with no smoking history and miR-183 relative expression level